CardiovascularORALGeneric

ROSUVASTATIN ZINC

Standard Dose

5MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: None (Tentative Approval)

Summary

Approval overview ROSUVASTATIN ZINC is listed in Drugs@FDA under application 202172 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ROSUVASTATIN ZINC Form and strength TABLET; ORAL - 5MG Sponsor WATSON LABS INC Submission history Latest submission status date: 2016-02-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview ROSUVASTATIN ZINC is listed in Drugs@FDA under application 202172 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient ROSUVASTATIN ZINC Form and strength TABLET; ORAL - 5MG Sponsor WATSON LABS INC Submission history Latest submission status date: 2016-02-12 00:00:00. Submission type: ORIG.

Monitoring

• Marketing status: None (Tentative Approval)
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.